A. Werner

发表

ReACT: Overall survival from a randomized phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma.

D. Tran, K. Fink, M. Mrugala, 2015 .

107 ReACT: Overall Survival From a Randomized Phase II Study of Rindopepimut (CDX-110) Plus Bevacizumab in Relapsed Glioblastoma

D. Tran, K. Fink, M. Mrugala, 2015 .

IMCT-08ReACT: LONG-TERM SURVIVAL FROM A RANDOMIZED PHASE II STUDY OF RINDOPEPIMUT (CDX-110) PLUS BEVACIZUMAB IN RELAPSED GLIOBLASTOMA

D. Tran, K. Fink, M. Mrugala, 2015 .

Cost-effectiveness of Lutetium [177Lu] oxodotreotide versus best supportive care with octreotide in patients with midgut neuroendocrine tumors in France

M. Blachier, O. Leeuwenkamp, J. Smith-Palmer, 2020, Journal of medical economics.

Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study

Kenneth L. Jones, A. Hattersley, S. Ellard, 2018, The Lancet Diabetes and Endocrinology.